{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/goals-outcome-measures/qof-indicators/","result":{"pageContext":{"chapter":{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators","depth":2,"htmlHeader":"<!-- begin field d7c589ff-0ea5-467d-aded-0085b61df681 --><h2>QOF indicators</h2><!-- end field d7c589ff-0ea5-467d-aded-0085b61df681 -->","summary":null,"htmlStringContent":"<!-- begin item 5c921684-4b1f-4fff-ae4c-ff67257c1a36 --><!-- begin field 5f1b00fd-0fb3-4aeb-9208-7991d83e51fd --><p><strong>Table 1. </strong>Indicators related to diabetes mellitus in the Quality and Outcomes Framework (QOF) of the General Medical Services (GMS) contract.</p><table data-table-id=\"9a64baff-bef0-4d33-8bec-acce014f47bb\"><thead><tr><th scope=\"col\">Indicator</th><th scope=\"col\">Points</th><th scope=\"col\">Achievement thresholds</th></tr></thead><tbody><tr><td><strong>Records</strong></td><td> </td><td> </td></tr><tr><td>DM017. The contractor establishes and maintains a register of all patients aged 17 or over with diabetes mellitus, which specifies the type of diabetes where a diagnosis has been confirmed</td><td>6</td><td> </td></tr><tr><td><strong>Ongoing management</strong></td><td> </td><td> </td></tr><tr><td>DM002. The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td><td>8</td><td>53–93%</td></tr><tr><td>DM003. The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 140/80 mmHg or less</td><td>10</td><td>38–78%</td></tr><tr><td>DM004. The percentage of patients with diabetes, on the register, whose last measured total cholesterol (measured within the preceding 12 months) is 5 mmol/L or less</td><td>6</td><td>40–75%</td></tr><tr><td>DM005. The percentage of patients with diabetes, on the register, who have a record of an albumin:creatinine ratio test in the preceding 12 months</td><td> </td><td> </td></tr><tr><td>DM006. The percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARB)</td><td>3</td><td>57–97%</td></tr><tr><td>DM007. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 59 mmol/mol or less in the preceding 12 months</td><td>17</td><td>35–75%</td></tr><tr><td>DM008. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 64 mmol/mol or less in the preceding 12 months</td><td>8</td><td>43–83%</td></tr><tr><td>DM009. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months</td><td>10</td><td>52–92%</td></tr><tr><td>DM011. The percentage of patients with diabetes, on the register, who have a record of retinal screening in the preceding 12 months</td><td> </td><td> </td></tr><tr><td>DM012. The percentage of patients with diabetes, on the register, with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes in previous ulcer) or 4) ulcerated foot within the preceding 12 months</td><td> </td><td>50–90%</td></tr><tr><td>DM014. The percentage of patients newly diagnosed with diabetes, on the register, in the preceding 1 April to 31 March who have a record of being referred to a structured education programme within 9 months after entry on to the diabetes register</td><td> </td><td>40–90%</td></tr><tr><td>DM018. The percentage of patients with diabetes, on the register, who have had influenza immunisation in the preceding 1 August to 31 March</td><td>6</td><td>55–95%</td></tr><tr><td>DM019. The percentage of patients with diabetes, on the register, without moderate or severe frailty in whom the last blood pressure reading (measured in the preceding 12 months) is 140/80 mmHg or less</td><td> </td><td>38–78%</td></tr><tr><td>DM020. The percentage of patients with diabetes, on the registers, without moderate or severe frailty in whom the last IFCC-HbA1c is 58 mmol/mol or less in the preceding 12 months</td><td> </td><td>35–75%</td></tr><tr><td>DM021. The percentage of patients with diabetes, on the register, with moderate or severe frailty in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months</td><td> </td><td>52–92%</td></tr><tr><td>DM022. The percentage of patients with diabetes aged 40 years and over, with no history of cardiovascular disease and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a CVD risk score of <10% recorded in the preceding 3 years)</td><td>4</td><td>50–90%</td></tr><tr><td>DM023. The percentage of patients with diabetes and a history of cardiovascular disease (excluding haemorrhagic stroke) who are currently treated with a statin</td><td>2</td><td>50–90%</td></tr><tr><td>SMOK002. The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months</td><td> </td><td>56–96%</td></tr><tr><td><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">BMA and NHS England, 2020</a>]</td><td> </td><td> </td></tr></tbody></table><!-- end field 5f1b00fd-0fb3-4aeb-9208-7991d83e51fd --><!-- end item 5c921684-4b1f-4fff-ae4c-ff67257c1a36 -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}